Apimeds Pharmaceuticals US (APUS) Long-Term Debt Issuances (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Long-Term Debt Issuances of -$64500.0 for Q4 2025, up 58.71% on a QoQ basis from -$156200.0 in Q3 2025, and up 62.82% year-over-year from -$39613.3 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at -$64500.0 for Q4 2025.
- Quarterly Long-Term Debt Issuances rose 62.82% year-over-year to -$64500.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29300.0 (changed N/A YoY) and the FY2025 annual result came in at $29300.0, down 61.7% from the prior year.
- Long-Term Debt Issuances was -$64500.0 for Q4 2025 at Apimeds Pharmaceuticals US, up from -$156200.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $232800.0 in Q2 2025 and bottomed at -$173500.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | -64,500.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64,500.00 |
| Dec 31, 2025 | -64,500.00 |
| Sep 30, 2025 | -156,200.00 |
| Sep 30, 2025 | -156,200.00 |
| Jun 30, 2025 | 232,800.00 |
| Jun 30, 2025 | 232,800.00 |
| Mar 31, 2025 | 17,200.00 |
| Mar 31, 2025 | 17,200.00 |
| Dec 31, 2024 | -173,500.00 |
| Dec 31, 2024 | -173,500.00 |
| Sep 30, 2024 | 150,000.00 |
| Sep 30, 2024 | 150,000.00 |